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Abstract
Background: Cure after treatment for human African trypanosomiasis (HAT) is assessed by examination of the cerebrospinal
fluid every 6 months, for a total period of 2 years. So far, no markers for cure or treatment failure have been identified in
blood. Trypanosome-specific antibodies are detectable in blood by the Card Agglutination Test for Trypanosomiasis (CATT).
We studied the value of a normalising, negative post-treatment CATT result in treated Trypanosoma brucei (T.b.) gambiense
sleeping sickness patients as a marker of cure.
Methodology/Principal Findings: The CATT/T.b. gambiense was performed on serum of a cohort of 360 T.b. gambiense
patients, consisting of 242 primary and 118 retreatment cases. The CATT results during 2 years of post-treatment follow-up
were studied in function of cure or treatment failure. At inclusion, sensitivity of CATT was 98% (234/238) in primary cases
and only 78% (91/117) in retreatment cases. After treatment, the CATT titre decreased both in cured patients and in patients
experiencing treatment failure.
Conclusions/Significance: Though CATT is a good test to detect HAT in primary cases, a normalising or negative CATT
result after treatment for HAT does not indicate cure, therefore CATT cannot be used to monitor treatment outcome.
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Introduction
Since none of the drugs for human African trypanosomiasis
(HAT) is 100% efficacious, it is recommended to follow-up
sleeping sickness patients every 6 months after treatment, for a
period of 2 years. Parasites may be difficult to detect in blood of
HAT patients experiencing treatment failure, therefore assessment
at follow-up visits relies mainly on lumbar puncture and
examination of the cerebrospinal fluid (CSF) for presence of
trypanosomes and white blood cell count. A patient is declared
cured when, within 2 years, no trypanosomes have been detected
and the CSF white blood cell count returned to normal [1].
Complete follow-up is seldom achieved because, when patients feel
well, they are reluctant to comply to the follow-up examinations
[2–5]. So far, no markers for cure or treatment failure after HAT
treatment have been identified in blood.
The card agglutination test for trypanosomiasis (CATT) is a
fast and simple agglutination test for detection of trypanosome
specific antibodies in blood of Trypanosoma brucei (T.b.) gambiense
infected patients [6]. With sensitivities between 87 and 98% and
specificities of around 95%, the CATT test is extensively used in
almost all HAT endemic areas for population screening, and has
contributed to the current success of HAT control programs
[7,8]. Given the fact that drugs for HAT are toxic, and the
specificity of CATT is limited, a confirmation step by
parasitological techniques is needed [7]. Trypanosome specific
antibodies, detectable by CATT have been demonstrated even 24
months after successful treatment in no less than 47% of gambiense
HAT patients [3,9,10]. A positive post-treatment CATT result is
therefore not indicative of treatment failure, but the predictive
value of a negative CATT after treatment has hitherto not been
evaluated. We explored the hypothesis that a normalising,
negative post-treatment CATT result indicates cure in gambiense
HAT and rules out treatment failure. If such CATT-normalising
patients could be released from further follow-up, this would lead
to major clinical and public health benefits as less lumbar
punctures would be required and less patients should be followed
for up to 24 months.
We report here on the pre- and post-treatment CATT serum
results in a cohort of primary and retreatment HAT cases infected
with T.b. gambiense.
Methods
Ethics statement
Sleeping sickness patients originate from a prospective obser-
vational study (THARSAT) [11]. The Commission for Medical
Ethics of the Prince Leopold Institute of Tropical Medicine,
Antwerp, Belgium and the Ethical Commission of the Ministry of
Public Health, Democratic Republic of the Congo approved the
study. Written informed consent was given by all study
participants prior to enrolment.
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The cohort consisted of 242 primary HAT cases that had never
been treated for HAT and of 118 retreatment cases previously
treated for HAT, but with trypanosomes detected in CSF at
inclusion. All cases were parasitologically confirmed before
enrolment and were (re)treated according to the national
guidelines: primary cases in first stage (n=41) were treated with
pentamidine, primary cases in second stage were treated with
melarsoprol (n=192) or eflornithine (n=9). Retreatment cases
were treated with melarsoprol (n=7), eflornithine (n=52),
melarsoprol nifurtimox combination therapy (n=57), melarsoprol
eflornithine combination therapy (n=1) or eflornithine nifurtimox
combination therapy (n=1). Patients were monitored for treat-
ment outcome during 2 years. The detailed description of the
clinical outcomes in the cohort is given elsewhere [11]. In brief,
out of 242 primary cases, the final outcome was cure in 90 (cure or
probable cure) and treatment failure in 118 (relapse, probable
relapse, or HAT related death during follow-up). 34 primary cases
were excluded from the analyses of post-treatment results since
they could not be classified as cured or treatment failure because
they were lost to follow-up, died during treatment or died over the
following 2 years from non-HAT related causes. Out of the 118
retreatment cases, 85 were cured and 16 experienced a new
treatment failure. Seventeen retreatment cases were lost to follow-
up, died during treatment or died over the following 2 years from
non-HAT related causes and were also excluded from the analyses
of post-treatment results.
CATT test
CATT/T.b. gambiense was performed following the titration-
method as described by the manufacturers [6] on serum taken
before treatment and at 3, 6, 12, 18 and 24 months post-
treatment. The end titre (highest dilution giving agglutination) was
determined. Patients with end titres $1:4 were considered CATT
positive, end titres ,1:4 were considered CATT negative.
Data analysis
The Chi square test or Fisher exact test (when the number of
observations in a cell was ,5) was performed for comparison of
proportions using a 95% confidence limit. Odds ratios (OR) with
binomial 95% confidence intervals (CI) were computed. STATA
version 10 was used for data analysis.
Results
CATT before treatment
The distribution of CATT end titres in primary and retreatment
cases at inclusion is presented in figure 1. The median end titre in
primary cases was 1:16 (interquartile range [IQR] 1:8–1:16,
mean6standard deviation: 1469), while it was 1:4 (IQR 1:4–1:8,
mean6standard deviation: 8614) in the retreatment cases
included in the cohort. Sensitivity of CATT was 98.3% in primary
cases (234/238, CI 95.8–99.5%) and 77.8% (91/117, CI 69.2–
84.9%) in retreatment cases. The median time between previous
and current treatment in retreatment patients was 10 months
(IQR 6–16 months, data available for 103/118 cases).
CATT after treatment
The CATT results after treatment - in function of cure or
treatment failure- are shown in figure 2.
In the 90 cured primary HAT cases, the median end titre
decreased to 1:8 (IQR 1:4–1:8) and 1:4 (IQR ,1:4–1:8) after 3
and 6 months respectively, and became ,1:4 afterwards. As
shown in figure 2, the proportion of CATT positives decreased in
the cured group over time to 52% (45/87) and 37% (30/81) at 6
and 12 months and to 18% (15/83) at the final follow-up visit at 24
months (also called test of cure). In the 118 primary cases who
experienced treatment failure within the 2 years of follow-up, the
median end titre decreased to 1:8 (IQR 1:4–1:8) after 3 months
and 1:4 (,1:4–1:8) after 6 and 12 months. The proportion of
CATT positives also decreased in function of time to 67% (44/66)
and 62% (13/21) at respectively 6 and 12 months after treatment.
No significant relationship between CATT positivity and
occurrence of treatment failure (p.0.05) could be observed at 3,
6 and 18 months post-treatment. A significantly higher proportion
of treatment failures cases tested positive with the CATT
compared to the cases that were cured 12 months (Chi square
test, p=0.040) and 24 months (Fisher exact test, p=0.027) after
treatment. The odds of a treatment failure case being CATT
positive are 2.76 (95% CI 1.03–7.4) and 13.6 (95% CI 1.32–140)
times greater than the odds of a cured case being CATT positive
12 and 24 months after treatment. In 7/113 primary cases
trypanosomes were detected in blood at time of relapse. Two of
them relapsed at 3 months with CATT titres 1:8 and 1:16 ; three
Figure 1. Distribution of CATT end titres in primary and
retreatment sleeping sickness cases at inclusion in the study.
doi:10.1371/journal.pntd.0000590.g001
Author Summary
The 2 year follow-up period required after treatment of
human African trypanosomiasis (HAT) patients is a major
challenge for patients and control programmes alike. The
patient should return every 6 months for lumbar puncture
and cerebrospinal fluid examination since, so far, no
markers for cure have been identified in blood. The Card
Agglutination Test for Trypanosomiasis (CATT) is a simple,
rapid test for trypanosome-specific antibody detection in
blood that is extensively used in endemic areas to screen
for HAT. We examined the value of a normalising CATT as a
marker for treatment outcome. We observed that CATT
titres decreased after treatment both in patients who
experienced treatment failure as well as in cured patients.
We conclude that CATT, though a good screening test, is
unreliable for monitoring treatment outcome. We also
showed that the sensitivity of CATT in relapse cases was as
low as 78%, and as a consequence some relapse cases
might be missed in screening programs if they have no
clinical signs yet.
CATT in HAT Follow-Up
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relapsed at 24 months with titres 1:8 and 1:16.
In the 85 retreatment cases who were cured after the current
treatment, the median end titre was 1:4 (IQR ,1:4–1:8, IQR
,1:4–1:4) after 3 and 6 months, and became ,1:4 afterwards.
The proportion of CATT positives decreased over time to 56%
(45/81) and 36% (28/77) at 6 and 12 months and 17% at the 24
months test of cure visit (figure 2). In 16 retreatment cases that
experienced a repeated treatment failure after the current
treatment, the median end titre was 1:4 (IQR ,1:4–1:4) and the
proportion of CATT positives 57% (8/14) 6 months post-
treatment. No significant relationship between CATT positivity
and occurrence of treatment failure (p.0.05) could be observed
during follow-up. In 3/16 of retreatment cases trypanosomes were
detected in blood at time of relapse. Their CATT titres were ,1:4
(relapse at 3 months), and ,1:4 and 1:16 (relapses at 6 months).
Discussion
We demonstrate for the first time that CATT sensitivity is low in
retreatment cases, and that CATT titres decrease after treatment
both in patients who experience treatment failure as well as in
cured patients.
Before treatment, the CATT sensitivity in primary cases falls
within the sensitivities previously reported for CATT in the
Democratic Republic of the Congo, and for HAT in general
[7,10]. The low sensitivity of 78% observed in retreatment cases is
explained by the decrease in CATT titre after a previous
treatment, and largely corresponds to the proportion of CATT
positives observed 6 and 12 months post-treatment within the
groups of treatment failures. The observed end titers are relatively
low, being in respectively 39% and 83% of the primary and
retreatment cases below 1:16. Treating serological cases based on
a CATT end titer $1:16, without parasitological evidence, might
miss some HAT cases.
Although it has been shown that trypanosome specific antibody
concentrations in blood of cured patients may persist up to 2 years
or longer after treatment [3,9,10,12], reports about the concen-
trations of specific antibodies in serum of sleeping sickness patients
who experience treatment failure are rare. In 22 relapsing patients,
Fre ´zil et al. [12] describe that the immunofluorescence test
remains positive in the majority of relapsing cases, but doubtful/
negative in only 1 case. In a small cohort of 32 relapse cases,
Mie ´zan et al. [3] describe a decreasing antibody concentration and
a CATT positivity rate of 94% at the moment relapse is
diagnosed.
A negative CATT after unsuccessful treatment might be
explained by trypanosomes that are cleared from peripheral
tissues, such as lymph and blood, but that survive in the brain and
thus do not trigger specific antibody production in the blood.
Our study has a number of limitations. As a consequence of the
diagnostic procedure used by the HAT control program to detect
HAT, the observed sensitivity of CATT of 98% in our group of
primary cases might be higher than in other patient cohorts.
Indeed, the patients in our cohort were identified as follows:
CATT on whole blood, alongside cervical lymph node palpation,
was used as a screening test and only those persons with a CATT
positive result on whole blood, or having enlarged cervical lymph
nodes underwent parasitological examinations for case confirma-
tion. Although part of the false negatives in CATT will be found
by cervical lymph node palpation, the true sensitivity of CATT in
the primary cases might be lower than 98%. The number of
treatment failures detected after $12 months is low, which
prevents us from making reliable estimates of a further de- or
increase in CATT titres after that time point, nor of the proportion
of CATT positives. Moreover, follow-up examinations in this
cohort- as in routine clinical care- were focused on cerebrospinal
fluid examination and the need for blood examinations may have
been given less importance by the nursing staff. As a consequence
the cohort does not allow us to check if relapsing patients with
trypanosomes in the blood had higher CATT titres than those
without, since in the majority, relapse was confirmed by finding of
trypanosomes in the CSF and no further blood examinations were
performed. Finally, the majority of primary cases in this study were
treated with the trypanolytic drug melarsoprol in an area of high
treatment failure rates. Although a similar trend was observed in
retreatment cases, who were treated differently, we cannot exclude
that results could differ in primary HAT patients treated with
other drugs.
Our findings have 2 practical implications. First, the consider-
able proportion of CATT negative results in cases experiencing
Figure 2. CATT positivity (%) during follow-up in primary HAT (left) and retreatment cases (right) who were cured or experienced
treatment failure after current treatment. The number of samples that was tested is indicated, whiskers show 95% confidence intervals.
doi:10.1371/journal.pntd.0000590.g002
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treatment CATT negative result does not necessarily indicate
cure. Knowing, moreover that a post-treatment CATT positive
result does not indicate treatment failure, makes us conclude that
CATT is unreliable for monitoring treatment outcome. Secondly,
screening programs for HAT should take into consideration that a
careful history about past HAT episodes is paramount, as the
sensitivity of CATT in relapse cases is not optimal. Cases
experiencing treatment failure are more likely to be false negative
in CATT than new cases and, as a consequence, might be missed
(i.e. not offered parasitological investigations) if they show no
clinical signs. These data might cast some doubt on the
performance of CATT as a screening test in the detection process,
given the fact that some relapse cases appear to be negative in the
CATT. Molecular -or other- diagnostics might eventually be taken
up in an improved algorithm for diagnosis or follow-up but further
investigation of these tests is necessary.
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